Research: Neurophysiology and neuroimaging

About our research

We study fundamental neurophysiological processes involved in sensory neuroscience, autonomic control, motor control and cognition.

Our research involves behavioural tests, advanced microscopy and electrophysiological recordings to study the mechanisms underlying a range of physiological processes, including synaptic function, cognition, neurovascular function, auditory processing and control of breathing.

We also use neuroimaging, identifying changes in the human brain associated with neurodegeneration, and novel targets for a range of different neurological conditions.

Neuronal signalling in memory

Cognitive flexibility involves the balancing of neuronal synaptic potentiation (acquisition of memories) with synaptic depression (modulation and updating previously acquired memories).

We research the role of specific protein kinase cascade in the role of long-term potentiation and long-term depression at CA1 synapses of the hippocampus using knockout (KO) mouse models.

Auditory processing

We investigate the neuroanatomical, molecular and neurophysiological functioning of the auditory pathway and neurological changes in auditory dysfunction in animals and humans.

We are particularly interested in physiological and metabolic changes in hearing impairment and their relationship to the development of dementia.

Neuro-vascular signalling

Neuron-glial-vascular communication is important for normal function of the central nervous system.

We use immunohistochemistry and electrophysiological approaches to study ion channels and receptors involved in glial communication.

Our primary focus is astrocyte communication within brainstem respiratory centres that control the drive to breathe. We aim to identify novel targets associated with neuropathology.

Neuroimaging for Neurodegenerative Disease

By using neuroimaging, we investigate the brain changes that underpin the symptoms seen in neurodegenerative conditions - especially Parkinson’s disease.

We aim to provide low-cost predictive biomarkers that can stratify people in clinical trials, and that can identify people at risk of future disease-related complications.